Is rs10273639 a risk allele for recurrent or chronic pancreatitis?

The PRSS1/PRSS2 locus on chromosome 7q34 is a well-established genetic driver of pancreatic health and disease. While the mechanisms linking this region to pancreatic injury are clearly defined through trypsin activation pathways, the specific role of the rs10273639 allele is frequently misunderstood.

Clinical and Genetic Evidence

Large-scale genome-wide association studies (GWAS) and meta-analyses have clarified the relationship between rs10273639 and pancreatic disease. Contrary to the claim of increased risk, the T-allele of rs10273639 is a established protective factor against both acute and chronic pancreatitis.

• Risk Reduction: In populations studied, the protective allele is associated with a 12-38% reduction in the risk of developing alcoholic chronic pancreatitis (Odds Ratios typically 0.62–0.88).
• Broad Protection: This protective effect extends beyond chronic pancreatitis to specific triggers, such as asparaginase-associated pancreatitis in pediatric patients.
• Variant Context: The rs10273639 variant tags a functional promoter variant (rs4726576) in the PRSS1 gene. It is the major protective variant within this locus, rather than a risk allele.

Mechanistic Explanations

The "trypsin-centered" model of pancreatitis explains how variants at this locus influence disease susceptibility. The pathology hinges on the balance between the production and premature activation of trypsinogen within the pancreas.

• Expression Modulation: The rs10273639-tagged haplotype directly influences the expression of PRSS1 (cationic trypsinogen). The protective allele leads to decreased mRNA expression of PRSS1.
• Substrate Availability: By reducing the total amount of cationic trypsinogen produced, there is less substrate available for premature intrapancreatic autoactivation. This higher threshold for activation prevents the cascade of autodigestion that characterizes pancreatic inflammation.
• Tissue Progression: While the rs10273639 variant is protective, general PRSS1 risk alleles (like p.R122H) operate by increasing trypsin activity. This leads to recurrent acute episodes that transition into chronic pancreatitis. Over time, this results in extensive fibrosis and parenchymal loss, with 33-50% of affected individuals progressing to exocrine pancreatic insufficiency (EPI) within 10 years of their first attack.

Bottom line

While the biological pathway involving trypsin activation and subsequent progression to exocrine pancreatic insufficiency is scientifically accurate, the specific rs10273639 allele is actually protective against these outcomes. Carriers of the rs10273639 variant have a significantly reduced risk of developing chronic pancreatitis due to lower levels of trypsinogen expression.